A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT00106535 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1196

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]
DRUG: Placebo
DRUG: Methotrexate

Sponsor

Hoffmann-La Roche